DERMATOLOGY.
SKIN MODEL.
DE-RISK ITCHING AND DESENSITIZING BEFORE CLINIC.
Benefits.
By providing human-relevant, functional readouts of nerve-ending activation and pruritic pathways, NETRI Skin model improves clinical risk assessment. It enables early evaluation of anti-itch or desensitizing compounds, predicts potential adverse effects on sensitive skin, and supports safer candidate selection while reducing reliance on animal models.
Description.
Create a platform to address sensitive skin or assess anti-itching compounds or on nerve endings with or without keratinocytes.
Readouts.
• MEA recordings.
• Mediators release dosage (ELISA).
• Imaging.
Advantages.
• Activate different pruritic pathways (activation of different receptors).
• Direct recording of nerve endings specifically.
• Activate TRPV1 receptor.
• Consistent coculture.
DERMATOLOGY.
POTENTIAL APPLICATIONS.
• Neuro-Inflammatory Skin Disorders: co-culture of hiPSC-derived sensory neurons and primary keratinocytes with cytokine pro-inflam. in neuronal ending & keratinocytes compartment.
• Pruritus: co-culture of hiPSC-derived sensory neurons and primary keratinocytes with ATP/Lactic Acid in neuronal ending & keratinocytes compartment.
• Wound Healing: co-culture of hiPSC-derived sensory neurons and skin organoids with wound tool in neuronal ending & keratinocytes compartment.
• Botox-Like: co-culture hiPSC-derived motor neurons and primary/patient muscle cells with compound in muscle compartment and stimulation (mechanical or electrical) in neuronal soma compartment.
• Cold Effect: co-culture of hiPSC-derived sensory neurons and primary keratinocytes with menthol in neuronal ending & keratinocytes compartment.
OUR OFFERS.
Initialization.
Creation of NaaS biology platform and NaaS Model for a target application.
• In Your Lab: Develop your NaaS Model on your own terms.
• At NETRI: Let NETRI Develop your NaaS Model.
Upscaling.
Build up of Digital NaaS model through Training Library of 100s of reference compounds.
• Pre-Licensing: Test your molecules using your NaaS Model.
Screening & Drug Design.
Transfer of methodology, devices and predictive model capabilities to client.
• Licensing: Screen your molecules using an existing NaaS Model.
Regulatory Approval.
Extension of approved NaaS Model to multiple clients. Larger deals with CROs to handle volumes.
• Licensing & milestones.
